ILP, with its low incidence of regional and systemic toxicity, is a valuable palliative treatment not only for patients with a disease confined to the limbs, but also for patients with metastatic melanoma with bulky or symptomatic diseases to improve their quality of life. This evidence concerns the gene XIAP and metastatic melanoma.